7 Tips To Protect Against AMD and Vision Loss After Age 50

If your vision is blurry or fuzzy, or if you notice that straight lines appear curved or wavy, they could be symptoms of ...
Healthline

How Wet AMD Apps Can Help with Low Vision

Apps may be available on your phone to help you monitor your wet AMD symptoms and assist you with everyday tasks such as reading, texting, and identifying objects. Advanced neovascular age-related ...
The American Journal of Managed Care

Brolucizumab Effective in Patients With Wet AMD, Regardless of Past Treatment

Wet age-related macular degeneration (AMD) can be managed using brolucizumab due to its efficacy. AMD is a leading cause of blindness worldwide, with its symptoms being irreversible once they progress ...
The American Journal of Managed Care

5 Things to Know During AMD Awareness Month

AMD primarily affects central vision, complicating activities like reading and driving, but does not cause complete blindness. Wet AMD involves abnormal blood vessel growth, while dry AMD progresses ...
Nasdaq

Outlook Therapeutics Announces NICE Recommendation for LYTENAVA™ in Wet AMD Treatment

Outlook Therapeutics, Inc. has announced a key development in the treatment of wet age-related macular degeneration (wet AMD) with the National Institute for Health and Care Excellence (NICE) ...

Arizona's Stevie Nicks has a rare eye disorder. Here's what we know

AMD is the leading cause of vision loss in one or both eyes among people 50 and older.Start the day smarter. Get all the news you need in your inbox each morning. Nicks is 76.
Healio

More than 300 patients assigned to treatment in phase 3 trial of Axpaxli for wet AMD

Please provide your email address to receive an email when new articles are posted on . Ocular Therapeutix announced that more than 300 patients have been randomly assigned in the SOL-1 phase 3 trial ...
Nasdaq

Outlook's ONS-5010 Receives Non-Inferior Results To Lucentis In Wet AMD Treatment

(RTTNews) - Outlook Therapeutics Inc. (OTLK), a biopharmaceutical company focused on ophthalmic treatments, on Thursday reported the positive data from its NORSE EIGHT trial evaluating ONS-5010 or ...
Benzinga.com

Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside

Needham initiated coverage on Ocular Therapeutix Inc OCUL, noting the company’s lead asset, Axpaxli, an investigational axitinib-based intravitreal implant for wet age-related macular degeneration ...

Regenxbio: Remains A "Buy Rating" Despite BLA Review Delay Of RGX-121 For Hunter Syndrome

Regenxbio's RGX-121 for Hunter syndrome saw its FDA review delayed to February 8, 2026, but strong 12-month surrogate endpoint data supports its ...
Morningstar

Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

ISELIN, N.J., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United ...